European-Huntington-Disease-Initiative (EHDI)-Study: Effect of riluzole on disease progression
A.C Ludolph, B Landwehrmeyer, J Garcia de Yebenes, B Dubois, H.P.H Kremer, H Przuntek, W Gaus, M Dib, W Fischer · Aktuelle Neurologie · 2005 · Heft 10
Bibliografische Angaben
Zusammenfassung
Riluzole has been shown to modify disease progression in amyotrophic lateral sclerosis (ALS) resulting in improved survival rates compared to controls. First studies in a transgenic mouse model of HD indicated an increase in survival time for these mice under riluzole and a fragmentation of neuronal intranuclear inclusions. Wether riluzole has an effect in HD patients in slowing down the disease progression was studied in the multi-national EHDI trial. The EHDI study was a phase III multicenter, double-blind, placebo-controlled trial to study the effect of riluzole 50mg b.i.d. for 36 months on the progression of…
